Outcome After Stereotactic Radiotherapy in ‘High-Risk’ Patients With Stage I Non-small Cell Lung Cancer (NSCLC)

Abstract

Excellent local control rates have been reported after stereotactic radiotherapy (SRT) for T1 non-small cell lung cancers (NSCLC). However, some reports suggest that toxicity is a problem with SRT for larger (T2) and centrally located tumors. We have performed SRT using 4D target definition in 256 patients since April 2003. The clinical outcome and early toxicity were assessed for ‘high-risk’ patients who were defined as those having T2 tumors or T1-T2 tumors adjacent to the hilus, mediastinum, heart or spinal cord.